iX Biopharma Ltd.
Climate Impact & Sustainability Data (2022-07 to 2023-06, July 2023 to June 2024)
Reporting Period: 2022-07 to 2023-06
Environmental Metrics
Total Carbon Emissions:937 t CO2-e (Scope 2)
Scope 2 Emissions:937 t CO2-e
Total Energy Consumption:1,095,311 kWh
Carbon Intensity:0.16 t CO2-e per $1K of sales in FY2023
ESG Focus Areas
- Environment
- Social
- Governance
- Economic
Environmental Achievements
- Decreased energy consumption per dollar of sales from 0.44 kWh to 0.19 kWh
Social Achievements
- Zero workplace fatality or serious injury
- Average training hours per employee increased to 49 hours
- Achieved 20% female representation on the Board
Governance Achievements
- Implemented a formal board diversity policy
- Established a robust governance framework to maintain integrity, transparency, accountability and discipline
Climate Goals & Targets
Short-term Goals:
- Maintain or lower electrical energy per dollar of sales
- Zero case of non-compliance with regulations concerning product health and safety
Environmental Challenges
- Anticipated increase in electricity consumption with increased manufacturing activities
Mitigation Strategies
- Evaluating the feasibility of on-site solar power generation at the Australia plant
Supply Chain Management
Supplier Audits: 2- and 4-year qualification and review cycles for suppliers of active ingredients and packaging materials
Responsible Procurement
- Supplier pre-qualification program
- Cyclical audit program
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI Standards, SGX-ST Practice Note 7F, TCFD
Sustainable Products & Innovation
- WaferiX and WaferlogiX drug delivery technologies
Reporting Period: July 2023 to June 2024
Environmental Metrics
Total Carbon Emissions:949 t CO2-e
Scope 2 Emissions:949 t CO2-e
Total Energy Consumption:1,059,707 kWh
Carbon Intensity:0.16 t CO2-e/$1K of Sales
ESG Focus Areas
- Environment
- Social
- Governance
- Economic
Environmental Achievements
- Reduced energy consumption by 3% despite a 1% increase in revenue.
- Re-formulated SL-NAD+ wafers to double the dosage, reducing resource consumption and potential waste by half.
Social Achievements
- Met the diversity target of 20% female representation on the Board.
- Successfully offered permanent positions to 2 casual rated personnel.
- Zero reportable workplace incidents.
Governance Achievements
- Implemented a formal board diversity policy.
- Robust governance framework to maintain integrity, transparency, accountability and discipline.
Climate Goals & Targets
Short-term Goals:
- Maintain or lower electrical energy per dollar of sales.
Environmental Challenges
- Anticipated increase in electricity consumption as commercial manufacturing activities increase.
- Increased Scope 2 GHGE due to power suppliers increasing their GHGE per unit of electricity supplied.
Mitigation Strategies
- Evaluating the feasibility of on-site solar power generation.
- Continued efforts to minimize carbon footprint by reducing total electricity consumption.
Supply Chain Management
Supplier Audits: 2- and 4-year qualification and review cycles for suppliers of active ingredients and packaging materials.
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI Standards, SGX-ST Practice Note 7F, TCFD
Sustainable Products & Innovation
- SL-NAD+ wafers (doubled dosage)
- Sublingual drug delivery technologies (WaferiX and WaferlogiX) aiming to reduce waste from single-use injectors.